Leap Therapeutics (LPTX) Revenue & Revenue Breakdown
Leap Therapeutics Revenue Highlights
Main Segment (Y)
License
Main Geography (Y)
License
Leap Therapeutics Revenue by Period
Leap Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $1.50M | - |
| 2020-12-31 | $1.50M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Leap Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Leap Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $634.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $375.00K | - |
| 2021-09-30 | $375.00K | - |
| 2021-06-30 | $375.00K | - |
| 2021-03-31 | $375.00K | - |
| 2020-12-31 | $375.00K | - |
| 2020-09-30 | $375.00K | - |
| 2020-06-30 | $375.00K | - |
| 2020-03-31 | $375.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Leap Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Leap Therapeutics Revenue Breakdown
Leap Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 |
|---|---|---|
| Royalty | - | - |
| License | $1.50M | $1.50M |
Leap Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 21: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|
| License | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K |
| Royalty | - | - | - | - | - | - | - | - |
Leap Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: License (100.00%).
Leap Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 |
|---|---|---|
| Royalty | - | - |
| License | $1.50M | $1.50M |
Leap Therapeutics's latest annual revenue breakdown by geography, as of Dec 21: License (100.00%).
Quarterly Revenue by Country
| Country | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|
| License | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K |
| Royalty | - | - | - | - | - | - | - | - |
Leap Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 21: License (100.00%).
Leap Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| LPTX | Leap Therapeutics | - | - |
| ELEV | Elevation Oncology | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
LPTX Revenue FAQ
What is Leap Therapeutics’s yearly revenue?
Leap Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. LPTX's yearly revenue for 2021 was $1.5M, representing an increase of 0% compared to 2020.
What is Leap Therapeutics’s quarterly revenue?
Leap Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). LPTX's quarterly revenue for Q4 2023 was $634K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Leap Therapeutics’s revenue growth rate?
Leap Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was 0%.
What are Leap Therapeutics’s revenue streams?
Leap Therapeutics's revenue streams in c 21 are License
What is Leap Therapeutics’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of Leap Therapeutics was License. This segment made a revenue of $1.5M, representing 100.00% of the company's total revenue.